Figure 2
From: HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer
Detection of HLA-A24 restricted, sur20–28 specific, CD8 postitive cells by interferon-γ and perforin. ELISPOT. CD8+ cells were isolated from PBL from two HLA-A24+ breast cancer patients (c24, c29), two HLA-A24+ melanoma patients (m3, m6), and four HLA-A24+ renal cancer patients (u1, u8, u13, u15). Spontaneous T-cell responses against Sur20–28 was measured by both interferon-γ and perforin ELISPOT for all patients. The average number of peptide specific IFNγ or perforin spots formed in response to Sur20–28 among 105 in vitro stimulated CD8+ cells. Non-specific spots are subtracted.